COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 2269: Articles 22681-22690  | Next

Rational design of a new class of protease inhibitors for the potential treatment of coronavirus diseases
Westberg, M., Su, Y., Zou, X., Hurst, B., Tarbet, B., Lin, M.
10.1101/2020.09.15.275891 — Posted: 2020-09-15 Discussion: Onsite
LOX-1+ immature neutrophils predict severe COVID-19 patients at risk of thrombotic complications
Combadiere, B., Adam, L., Quentric, P., Rosenbaum, P., Dorgham, K., Bonduelle, O., Parizot, C., Sauce, D., Mayaux, J., Luyt, C.-E., Boissonnas, A., Amoura, Z., Pourcher, V., Miyara, M., Gorochov, G., Guihot, A., Combadiere, C.
10.1101/2020.09.15.293100 — Posted: 2020-09-15
SARS-CoV-2 ribosomal frameshifting pseudoknot: Improved secondary structure prediction and detection of inter-viral structural similarity
Trinity, L., Lansing, L., Jabbari, H., Stege, U.
10.1101/2020.09.15.298604 — Posted: 2020-09-15
Levels of genetic diversity of SARS-CoV-2 virus: reducing speculations about the genetic variability of the virus in South America
Filho, C. B. d. N., Ramos, R. d. S., Paulino, A. J., Venancio, D. B. R., Felix, P. T.
10.1101/2020.09.14.296491 — Posted: 2020-09-15
Emergence and expansion of highly infectious spike:D614G mutant SARS-CoV-2 in central India
Sharma, S., Dash, P. K., Sharma, S. K., Srivastava, A., Kumar, J. S., Karothia, B. S., Chelvam, K. T., Singh, S., Gupta, A., Yadav, R. G., Yadav, R., S, G. T., Kushwah, P., Bhushan, R., Nagar, D. P., Nandan, M., Kumar, S., Thavaselvam, D., Dubey, D. K.
10.1101/2020.09.15.297846 — Posted: 2020-09-15
The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro
Konrat, R., Papp, H., Szijarto, V., Gesell, T., Nagy, G., Madai, M., Zeghbib, S., Kuczmog, A., Lanszki, Z., Helyes, Z., Kemenesi, G., Jakab, F., Nagy, E.
10.1101/2020.09.15.296228 — Posted: 2020-09-15
Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
Schaefer, A., Muecksch, F., Lorenzi, J. C. C., Leist, S. R., Cipolla, M., Bournazos, S., Schmidt, F., Gazumyan, A., Baric, R. S., Robbiani, D. F., Hatziioannou, T., Ravetch, J. V., Bieniasz, P. D., Nussenzweig, M. C., Sheahan, T. P.
10.1101/2020.09.15.298067 — Posted: 2020-09-15
Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction
Lin, C., Li, Y., Yuan, M., Huang, M., Liu, C., Du, H., Pan, X., Wen, Y., Xu, X., Xu, C., Chen, J.
10.1101/2020.09.14.295956 — Posted: 2020-09-15
Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy
Basar, R., Uprety, N., Ensley, E., Daher, M., Klein, K., Martinez, F., Aung, F., Shanley, M., Hu, B., Gokdemir, E., Mendt, M., Reyes Silva, F., Acharya, S., Laskowski, T., Muniz-Feliciano, L., Banerjee, P., Li, Y., Li, S., Melo Garcia, L., Lin, P., Shaim, H., Yates, S. G., Marin, D., Kaur, I., Rao, S., Mak, D., Lin, A., Miao, Q., Dou, J., Chen, K., Champlin, R., Shpall, E. J., Rezvani, K.
10.1101/2020.09.15.298547 — Posted: 2020-09-15
Predictors of characteristics associated with negative SARS-CoV-2 PCR test despite proven disease and association with treatment and outcomes.The COVID-19 RT-PCR Study.
Lascarrou, J. B., Colin, G., Le Thuaut, A., Serck, N., Ohana, M., Sauneuf, B., Geri, G., Mesland, J. B., Ribeyre, G., Hussenet, C., Boureau, A. S., Gille, T.
10.1101/2020.09.14.20194001 — Posted: 2020-09-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).